A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
Adiposity
Alleles
Diet, Healthy
Exercise
Female
Genetic Predisposition to Disease
Healthy Lifestyle
Humans
Insulin Resistance
Intra-Abdominal Fat
Lipase
/ genetics
Liver
/ metabolism
Male
Membrane Proteins
/ genetics
Non-alcoholic Fatty Liver Disease
/ epidemiology
Polymorphism, Genetic
Prevalence
Thinness
Triglycerides
/ metabolism
body mass index
fatty liver
lean
non-alcoholic fatty liver disease
obesity
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
26
10
2020
received:
07
06
2020
accepted:
10
11
2020
pubmed:
21
11
2020
medline:
3
11
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of hepatic disorders. It represents a wide range of chronic liver diseases in patients with no history of significant alcohol consumption, starting with simple steatosis and progressing towards non-alcoholic steatohepatitis, cirrhosis, and ultimately hepatocellular carcinoma. NAFLD is usually associated with type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, and obesity. This disease has mostly been studied in obese individuals; however, it has been widely reported and studied among the lean/non-obese population in recent years. The pathogenesis of NAFLD in non-obese patients is associated with various genetic predispositions, particularly a patatin-like phospholipase domain-containing protein 3 G allele polymorphism, which results in the accumulation of triglyceride in the liver and resistance to insulin. Additionally, dietary factors such as high fructose consumption seem to play a substantial role in the pathology of non-obese NAFLD. Although there is not enough evidence on the treatment of NAFLD in non-obese patients, the standard approach is to advise altering one's lifestyle in order to diminish visceral adiposity. Dietary modification, weight loss, and increased physical activity are highly recommended. We aimed to review and summarize the existing information on the prevalence, pathogenesis, genetic predispositions, diagnosis, and treatment of NAFLD in non-obese patients according to the latest literature.
Substances chimiques
Membrane Proteins
0
Triglycerides
0
Lipase
EC 3.1.1.3
adiponutrin, human
EC 3.1.1.3
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1497-1507Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol. 2018; 67: 328-357.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol. 2016; 64: 73-84.
Mellinger JL, Pencina KM, Massaro JM et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J. Hepatol. 2015; 63: 470-476.
Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment. Pharmacol. Ther. 2017; 46: 85-95.
Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: either non-obese or obese Chinese population. Hepatob. pancreatic diseases intern: HBPD INT. 2018; 17: 45-48.
Lu FB, Hu ED, Xu LM et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert. Rev. Gastroenterol. Hepatol. 2018; 12: 491-502.
Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo. Clin. Proc. 1980; 55: 434-438.
Younossi ZM, Stepanova M, Negro F et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012; 91: 319-327.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J. Hepatol. 2017; 67: 862-873.
Liu C-J. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J. Gastroenterol. Hepatol. 2012; 27: 1555-1560.
Leung JC, Loong TC, Wei JL et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017; 65: 54-64.
Wei JL, Leung JC, Loong TC et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am. J. Gastroenterol. 2015; 110: 1306-1314 quiz 15.
Shi Y, Wang Q, Sun Y et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. J. Clin. Gastroenterol. 2020; 54: 378-387.
Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: meta-analytic assessment of prevalence, genetic, metabolic and histological profiles. J. Dig. Dis. 2020.
Younes R, Bugianesi E. NASH in lean individuals. Semin. Liver Dis. 2019; 39: 86-95.
Kim D, Kim WR. Nonobese fatty liver disease. Clinl. Gastroente. Hepatology: the Official Clinical Prac. J. Ame. Gastroentero. Asso. 2017; 15: 474-485.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet. 2004;363(9403):157-63.
Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet (London, England). 2005; 366: 1059-1062.
Chen CH, Huang MH, Yang JC et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J. Clin. Gastroenterol. 2006; 40: 745-752.
Kim HJ, Kim HJ, Lee KE et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 2169-2175.
Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-1395.
Conjeevaram Selvakumar PK, Kabbany MN, Lopez R, Rayas MS, Lynch JL, Alkhouri N. Prevalence of suspected nonalcoholic fatty liver disease in lean adolescents in the United States. J. Pediatr. Gastroenterol. Nutr. 2018; 67: 75-79.
Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008; 134: 1369-1375.
Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48: 634-642.
Feldman A, Eder SK, Felder TK et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am. J. Gastroenterol. 2017; 112: 102-110.
Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 2010; 16: 1941-1951.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005; 115: 1343-1351.
García-Monzón C, Lo Iacono O, Mayoral R et al. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J. Hepatol. 2011; 54: 142-152.
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010; 51: 679-689.
Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020; 11: 802.
Feng R, Luo C, Li C et al. Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case-control study. Lipids Health Dis. 2017; 16: 165.
Smith GI, Shankaran M, Yoshino M et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J. Clin. Invest. 2020; 130: 1453-1460.
Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie. 2005; 87: 81-86.
Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008; 134: 424-431.
Guo Z, Li M, Han B, Qi X. Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis. Diges. liver disease: official j. Italian Soc. Gastro. Italian Assoc. Study Liv. 2018; 50: 1153-1162.
Kim JJ, Kim D, Yim JY et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2017; 45: 1403-1412.
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012; 142: 711-25.e6.
Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 2008; 168: 1609-1616.
Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? J gastro and liver diseases: JGLD 2012; 21: 205-208.
van der Poorten D, Milner KL, Hui J et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008; 48: 449-457.
Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis. Endocri. meta. (Seoul, Korea). 2020; 35: 165-176.
Unamuno X, Gómez-Ambrosi J, Rodríguez A, Becerril S, Frühbeck G, Catalán V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur. J. Clin. Invest. 2018; 48: e12997.
Bai Y, Sun Q. Macrophage recruitment in obese adipose tissue. Obesity rev: an offi. j. Intern. Assoc. St. Obe. 2015; 16: 127-136.
Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. 2014; 20: 18070-18091.
Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clinical nutrition (Edinburgh, Scotland). 2019; 38: 975-981.
Drolet R, Bélanger C, Fortier M et al. Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring, Md). 2009; 17: 424-430.
Motoshima H, Wu X, Sinha MK et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 2002; 87: 5662-5667.
Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease. J. gastro. and liver diseases: JGLD. 2016; 25: 159-165.
Kapil S, Duseja A, Sharma BK et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2016; 31: 213-221.
Shanab AA, Scully P, Crosbie O et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 2011; 56: 1524-1534.
Shah A, Shanahan E, Macdonald GA et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis. 2017; 37: 388-400.
Wijarnpreecha K, Lou S, Watthanasuntorn K et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eu.r J. Gastroenterol. Hepatol. 2020; 32: 601-608.
Wijarnpreecha K, Werlang ME, Watthanasuntorn K et al. Obesity and risk of small intestine bacterial overgrowth: a systematic review and meta-analysis. Dig. Dis. Sci. 2020; 65: 1414-1422.
Asgari-Taee F, Zerafati-Shoae N, Dehghani M, Sadeghi M, Baradaran HR, Jazayeri S. Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur. J. Nutr. 2019; 58: 1759-1769.
Chen H, Wang J, Li Z et al. Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis. Int. J. Environ. Res. Public. Health. 2019; 16.
Assy N, Nasser G, Kamayse I et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Canadian j. gastroent. = J. canadien de gastroente. 2008; 22: 811-816.
Khalatbari-Soltani S, Imamura F, Brage S et al. The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. BMC Med. 2019; 17: 19.
Liu X, Peng Y, Chen S, Sun Q. An observational study on the association between major dietary patterns and non-alcoholic fatty liver disease in Chinese adolescents. Medicine. 2018; 97: e0576.
Ryan MC, Itsiopoulos C, Thodis T et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013; 59: 138-143.
Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J. invest med: the official publi. Ame. Fed. Clin. Res. 2017; 65: 1102-1115.
Perdomo CM, Frühbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients 2019; 11.
Li C, Guo P, Okekunle AP et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J. Gastroenterol. Hepatol. 2019; 34: 256-262.
Xia Y, Zhang S, Zhang Q et al. Insoluble dietary fibre intake is associated with lower prevalence of newly-diagnosed non-alcoholic fatty liver disease in Chinese men: a large population-based cross-sectional study. Nutr. Metab. 2020; 17: 4.
Bjermo H, Iggman D, Kullberg J et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am. J. Clin. Nutr. 2012; 95: 1003-1012.
Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br. J. Nutr. 2013; 109: 1096-1104.
Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008; 40: 1461-1465.
Niriella MA, Kasturiratne A, Pathmeswaran A et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatology. intern. 2019; 13: 314-322.
Oniki K, Saruwatari J, Izuka T et al. Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects. PLoS ONE. 2015; 10: e0132640.
Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J. Biol. Chem. 2011; 286: 37085-37093.
Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011; 53: 1883-1894.
Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes. 2013; 62: 1109-1120.
Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J. Biomed. Res. 2018; 32: 389-400.
Dongiovanni P, Petta S, Maglio C et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015; 61: 506-514.
Liu YL, Reeves HL, Burt AD et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 2014; 5: 4309.
Chen F, Esmaili S, Rogers GB et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology 2020; 71: 1213-1227.
Wang Q, You H, Ou X et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatology intern. 2019; 13: 766-776.
Adams LA, Marsh JA, Ayonrinde OT et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. J. Gastroenterol. Hepatol. 2012; 27: 1520-1527.
Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 362: 1082-1089.
Jain V, Kumar A, Ahmad N et al. Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents. J. pediatric. endocrin. metab: JPEM. 2019; 32: 749-758.
Kumar A, Shalimar WGK, Gupta V, Sachdeva MP. Genetics of nonalcoholic fatty liver disease in Asian populations. J. Genet. 2019; 98.
Zeng J, Yang RX, Sun C et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World. J. Gastroenterol. 2020; 26: 1792-1804.
Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand. J. Gastroenterol. 2015; 50: 341-346.
Vos B, Moreno C, Nagy N et al. Lean non-alcoholic fatty liver disease (lean-NAFLD): a major cause of cryptogenic liver disease. Acta. Gastroenterol. Belg. 2011; 74: 389-394.
Kumar R, Rastogi A, Sharma MK et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease? Indian j. endocri. meta. 2013; 17: 665-671.
Bernhardt P, Kratzer W, Schmidberger J, Graeter T, Gruener B. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis. BMC Res. Notes. 2018; 11: 101.
EASL-EASD-EASO. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402.
Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J. Gastroenterol: WJG. 2014; 20: 7392.
Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann. Gastroenterol. 2012; 25: 218-231.
Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010; 53: 372-384.
Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321.
Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap. Adv. Gastroenterol. 2012; 5: 199-207.
Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J. Hepatol. 2018; 68: 305-315.
Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017; 66: 1486-1501.
Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2018; 47: 16-25.
Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of cohort study. Clin. Res. Hepatol. Gastroenterol. 2017; 41: 629-634.
Younossi ZM, Loomba R, Anstee QM et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018; 68: 349-360.
Wong VW, Chan RS, Wong GL et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J. Hepatol. 2013; 59: 536-542.
Jin YJ, Kim KM, Hwang S et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J. Gastroenterol. Hepatol. 2012; 27: 1341-1347.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149: 367-378 e5; quiz e14-5.
Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms. Liver intern: official j. Intern. Asso. Study. Liv. 2017; 37: 936-949.
Trovato FM, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Cli. nutri. (Edinburgh, Scotland). 2015; 34: 86-88.
Bambha K, Wilson LA, Unalp A et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver intern: official j. Intern Asso. Study. Liv. 2014; 34: 1250-1258.
Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2012; 35: 76-82.
Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012; 55: 429-436.
Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2017; 29: e8-e12.
Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clinical. nutrition. (Edinburgh, Scotland). 2019; 38: 2552-2557.
Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J. Intern. Med. 2018; 33: 64-74.
Li Y, He F, He Y et al. Dose-response association between physical activity and non-alcoholic fatty liver disease: a case-control study in a Chinese population. BMJ. Open. 2019; 9: e026854.
Hashida R, Kawaguchi T, Bekki M et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J. Hepatol. 2017; 66: 142-152.
Shen J, Wong GL, Chan HL et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2015; 30: 139-146.
Sevastianova K, Kotronen A, Gastaldelli A et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am. J. Clin. Nutr. 2011; 94: 104-111.
Marzuillo P, Grandone A, Perrone L, del Giudice EM. Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J. Hepatol. 2013; 59: 1143-1144.
Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 1675-1685.
Cusi K, Orsak B, Bril F et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 2016; 165: 305-315.
Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006; 355: 2297-2307.
Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed. reports. 2013; 1: 57-64.
Mazhar K. The future of nonalcoholic fatty liver disease treatment. Med. Clin. 2018.
Dong Y, Lv Q, Li S et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol. 2017; 41: 284-295.
Shetty A, Syn W-K. Current treatment options for nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 2019; 35: 168-176.
Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. (London, England). 2016; 387: 679-690.
Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology. 2008; 134: 2101-2110.
Enjoji M, Machida K, Kohjima M et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010; 9: 29.
Lee HY, Jun DW, Kim HJ et al. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J. Intern. Med. 2019; 34: 296-304.
Nakade Y, Murotani K, Inoue T et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis. Hepa. rese: the offi. j. Japan Soc. Hep. 2017; 47: 1417-1428.
Mofidi F, Poustchi H, Yari Z et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br. J. Nutr. 2017; 117: 662-668.
Fukuda T, Hamaguchi M, Kojima T et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver intern: official j. Intern. Asso. Study. Liv. 2016; 36: 275-283.
Sinn DH, Kang D, Cho SJ et al. Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. Eur. J. Endocrinol. 2019.
Kim SS, Cho HJ, Kim HJ et al. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Diges. liver. disease: official. jItalian. Soc. of Gastro. Italian Assoc. Study Liv. 2018; 50: 370-377.
Sung KC, Seo DC, Lee SJ, Lee MY, Wild SH, Byrne CD. Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. Nutrition, metabolism, and cardiova dise: NMCD. 2019; 29: 489-495.
Gonzalez-Cantero J, Martin-Rodriguez JL, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Insulin resistance in lean and overweight non-diabetic Caucasian adults: study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS ONE. 2018; 13: e0192663.
Huang JF, Tsai PC, Yeh ML et al. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J. Formos. Med. Assoc. = Taiwan yi zhi. 2020; 119: 89-96.
Hagström H, Nasr P, Ekstedt M et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol. commu. 2018; 2: 48-57.
Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J. Intern. Med.: 2020.
Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin. Diabetes. 2019; 37: 65-72.
Koot BGP, Nobili V. Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance? Obesity Rev: An Offi. J. Intern. Assoc. St. Obe. 2017; 18: 1050-1060.
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J. Gastroenterol. 2018; 24: 3361-3373.
Vos MB, Abrams SH, Barlow SE et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J. Pediatr. Gastroenterol. Nutr. 2017; 64: 319-334.
Yao J, Dai Y, Zhang J, Zhang X, Zheng R. Association between serum ferritin level and nonalcoholic fatty liver disease in a non-obese Chinese population: a cross-sectional study. Clin. Lab. 2019; 65. https://doi.org/10.7754/Clin.Lab.2019.181250
Hsu CL, Wu FZ, Lin KH et al. Role of fatty liver index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup. Clin. Transl. Gastroenterol. 2019; 10: 1-8.
Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta. Med. Indones. 2017; 49: 136-147.
Jaruvongvanich V, Ahuja W, Wirunsawanya K, Wijarnpreecha K, Ungprasert P. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2017; 29: 1031-1035.
Javed A, Jumean M, Murad MH et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta-analysis. Pediatr. Obes. 2015; 10: 234-244.
Okorodudu DO, Jumean MF, Montori VM et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Intern. j. obesity (2005). 2010; 34: 791-799.
Barreira TV, Broyles ST, Gupta AK, Katzmarzyk PT. Relationship of anthropometric indices to abdominal and total body fat in youth: sex and race differences. Obesity. (Silver Spring, Md). 2014; 22: 1345-1350.
Ha Y, Seo N, Shim JH et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: a case-control study. J. Gastroenterol. Hepatol. 2015; 30: 1666-1672.
Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am. J. Clin. Nutr. 2007; 86: 353-359.
Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2013; 47: 280-286.
Naderian M, Kolahdoozan S, Sharifi AS et al. Assessment of lean patients with non-alcoholic fatty liver disease in a middle income country; prevalence and its association with metabolic disorders: a cross-sectional study. Arch. Iran Med. 2017; 20: 211-217.